Meanwhile, recurrent mutations in DOCK2 may led to abnormal activation of RAC1, which promoted overexpression of NF-κB and Wnt/β-catenin pathways, further improving the development of CRC (Myant et al., 2013; Yu et al., 2015). The gene discussed is DOCK2; the disease is colorectal carcinoma.